Alert

Recommended Alerts

Sign Up For Alerts

China Aims to Introduce Routine Drug and Device Overseas Inspections

China’s drug and device regulator recently announced a set of rules signaling increased scrutiny of foreign drug and device companies. On December 26, 2018, the National Medical Products Administration (the “NMPA”) released the Regulations for Drug and Device Overseas Inspection (the “Regulations”). The Regulations set out a working procedure for the NMPA to verify whether foreign drug and device companies’ R&D and manufacturing activities adhere to applicable PRC statutory requirements and standards. Drugs and devices that are approved or intended for marketing in China will be subject to the Regulations.

Read More

China FDA Publishes Draft Measures to Accelerate Medical Device Approvals

Practices: China Life Sciences

Printer-Friendly Version

Cookie Settings